KR20230038721A - 항-tau 항체 - Google Patents

항-tau 항체 Download PDF

Info

Publication number
KR20230038721A
KR20230038721A KR1020237003616A KR20237003616A KR20230038721A KR 20230038721 A KR20230038721 A KR 20230038721A KR 1020237003616 A KR1020237003616 A KR 1020237003616A KR 20237003616 A KR20237003616 A KR 20237003616A KR 20230038721 A KR20230038721 A KR 20230038721A
Authority
KR
South Korea
Prior art keywords
seq
sequence
amino acid
specific binding
binding molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237003616A
Other languages
English (en)
Korean (ko)
Inventor
찰스 로버트 해링턴
소만 수미야 팔리일
앤드류 저스틴 래드클리프 포터
클로드 미셸 위시크
모하마드 아라스투
루이스 커크 페니
리차드 로프트하우스
Original Assignee
지틴벤트 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 지틴벤트 리미티드 filed Critical 지틴벤트 리미티드
Publication of KR20230038721A publication Critical patent/KR20230038721A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020237003616A 2020-07-10 2021-07-09 항-tau 항체 Pending KR20230038721A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2010652.2A GB202010652D0 (en) 2020-07-10 2020-07-10 Anti-tau antibodies
GB2010652.2 2020-07-10
PCT/EP2021/069160 WO2022008719A1 (en) 2020-07-10 2021-07-09 Anti-tau antibodies

Publications (1)

Publication Number Publication Date
KR20230038721A true KR20230038721A (ko) 2023-03-21

Family

ID=72140057

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237003616A Pending KR20230038721A (ko) 2020-07-10 2021-07-09 항-tau 항체

Country Status (10)

Country Link
US (1) US20230257452A1 (https=)
EP (1) EP4178980A1 (https=)
JP (1) JP7796719B2 (https=)
KR (1) KR20230038721A (https=)
CN (1) CN116194479A (https=)
AU (1) AU2021306653A1 (https=)
CA (1) CA3185175A1 (https=)
GB (1) GB202010652D0 (https=)
TW (1) TWI912331B (https=)
WO (1) WO2022008719A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250147051A1 (en) * 2022-01-12 2025-05-08 Gtinvent Limited Method for detecting a tau protein in a saliva sample
KR20240134175A (ko) * 2022-01-12 2024-09-06 지틴벤트 리미티드 샘플에서 타우(tau) 단백질 단편을 검출하기 위한 방법

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
US20140303041A1 (en) * 2004-04-15 2014-10-09 University Of Florida Research Foundation Inc. In vitro diagnostic devices for nervous system injury and other neural disorders
ES2349322T7 (es) 2006-03-29 2019-10-17 Wista Lab Ltd Sales de 3,7-diamino-10H-fenotiazina y su utilización
WO2007110630A1 (en) 2006-03-29 2007-10-04 Wista Laboratories Ltd. Thioninium compounds and their use
JP5898701B2 (ja) 2011-02-11 2016-04-13 ウィスタ ラボラトリーズ リミテッド フェノチアジンジアミニウム塩およびそれらの使用
CA2896066C (en) * 2012-12-21 2022-07-12 Biogen Ma Inc. Human anti-tau antibodies
GB201312226D0 (en) * 2013-07-08 2013-08-21 Adx Neurosciences Improved antibodies
BR112016010454A2 (pt) * 2013-11-27 2017-12-05 Ipierian Inc métodos para tratar uma taupatia
CA3032692A1 (en) 2016-08-09 2018-02-15 Eli Lilly And Company Combination antibody therapy for the treatment of neurodegenerative diseases
UA128383C2 (uk) * 2016-12-07 2024-07-03 Дженентек, Інк. Антитіло до тау-білка та спосіб його застосування
EP3601337A1 (en) * 2017-03-28 2020-02-05 Genentech, Inc. Methods of treating neurodegenerative diseases
US20250147051A1 (en) * 2022-01-12 2025-05-08 Gtinvent Limited Method for detecting a tau protein in a saliva sample

Also Published As

Publication number Publication date
AU2021306653A1 (en) 2023-03-02
US20230257452A1 (en) 2023-08-17
TW202214686A (zh) 2022-04-16
JP2023533768A (ja) 2023-08-04
EP4178980A1 (en) 2023-05-17
GB202010652D0 (en) 2020-08-26
JP7796719B2 (ja) 2026-01-09
TWI912331B (zh) 2026-01-21
CA3185175A1 (en) 2022-01-13
WO2022008719A1 (en) 2022-01-13
CN116194479A (zh) 2023-05-30

Similar Documents

Publication Publication Date Title
US10400034B2 (en) Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
TW201103560A (en) Use of an anti-Tau pS422 antibody for the treatment of brain diseases
JP2018139530A (ja) 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
KR102599010B1 (ko) 항-herv-k 엔벨로프 항체 및 그 용도
JP2021515556A (ja) 抗ｐｈｆ−タウ抗体及びその使用
TWI892069B (zh) 用於偵測Tau蛋白或其片段的方法與套組
KR20230038721A (ko) 항-tau 항체
US11472869B2 (en) Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
RU2855123C1 (ru) Антитела против тау
US20250355001A1 (en) Method for detecting a tau protein fragment in a sample
HK1166331B (en) Use of an anti-tau ps422 antibody for the treatment of brain diseases

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230131

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240705

Comment text: Request for Examination of Application